Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Controlled Phase II Trial of Temozolomide With or Without Cannabinoids in Patients With Recurrent Glioblastoma

NCT05629702 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT05629702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05629702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Controlled Phase II Trial of Temozolomide With or Without Cannabinoids in Patients With Recurrent Glioblastoma
Lead sponsor
University of Birmingham
Phase
Phase 2
Overall status
Recruiting
Start date
February 3, 2023
Completion date
April 30, 2027
Enrollment
120 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, brain tumor, recurrent, cannabis, glioblastoma